fashion -WSS

fashion

author：focus 2025-09-28 23:11:28 - browse：141

Several amyloid plaques forming between neurons in a brain — Amyloid plaques forming between neurons. Adobe

The Food and Drug Administration on Thursday granted full approval to the first therapy for Alzheimer’s disease clearly shown to slow the cognitive decline associated with the disease — a milestone in treatment, even if the benefits are modest.

The drug, called Leqembi, was developed by Eisai, the Japanese pharmaceutical company, and sold in partnership with Biogen. It previously secured conditional approval in January. The FDA’s decision will broaden patient access to the drug under the Medicare program and is likely to boost sales, even as Leqembi’s benefits and safety risks continue to be a source of debate.

Leqembi’s full, or traditional, approval was supported by results of a large clinical trial in which the drug slowed the rate of cognitive and functional decline by 27% compared to a placebo. Leqembi also beat placebo on a series of secondary measures of Alzheimer’s, and it had a dramatic effect on clearing toxic brain plaques called beta-amyloid, which play a role in the progression of the disease.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： State Dept. review finds Biden bears some blame for Afghanistan failures
Next article： YouTube cracks down on misinformation on cancer treatment

WSS

FDA's naming rule on biosimilars has undermined competition

Indictment alleges Trump's ex

What to know about the judge who will handle the Trump case

Aspartame and sugar

Megan Rapinoe shares emotional post following US Women's World Cup exit

Roche subsidiary Foundation Medicine opens new headquarters

focus

fashion

hotspot

DIEP, the 'gold standard' of breast reconstruction, is under threat

Patient advocates debate FDA's accelerated approval process

The cancer drug shortage isn’t new — and neither are the solutions

What to know about the judge who will handle the Trump case

Walensky prepares to leave CDC — and Congress — behind

Primary care physicians play key roles in Alzheimer's management

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Readout Newsletter: Merck, Vertex, and Viking updates

What does generative AI mean for health care? We asked experts

Surge in Apellis stock fueled by confidence in safety of its eye drug

hotspot

Study says nonprofit hospitals fall short in charity care spending

Judge sides with young activists in first

Judge sides with young activists in first

Abortion pill Supreme Court ruling could impact entire drug industry

States should stop sabotaging methadone treatment reform

Biogen’s boardroom scandal saddles CEO with first crisis

entertainment

hotspot

focus

entertainment